If your business touches in vitro diagnostic (IVD) reagents or medical devices, the trap most people fall into across markets isn’t “is this specific product good” — it’s “the same product can land in a completely different risk class depending on the country, because the classification methodology itself is different.” This article covers only the regulatory framework and process — no clinical judgment or diagnostic-accuracy content — to help you understand how the US FDA, China’s NMPA, and the EU’s MDR/IVDR actually work, why confusion happens so easily, and a specific deadline (January 1, 2027) worth knowing if you deal with Chinese IVD products.
1. Three systems, three fundamentally different classification methodologies
This is the most overlooked, and most important, point: the US, China, and EU don’t just apply different risk thresholds — the very method for determining which class a product belongs to is different.
- US FDA: a three-tier system (Class I/II/III), determined primarily by comparing the product to a similar, already-cleared device (a “predicate device”). Most products are classified by matching against a similar product already in the FDA’s database, which determines the product code and corresponding class.
- China’s NMPA: also three tiers (Class I/II/III), but determined primarily by looking up the official Classification Catalogue — a document listing specific product categories and 6-digit product codes; you look up your device type and the catalogue tells you the class directly. As of 2026, the medical device catalogue covers 22 major categories, with a separate IVD-specific catalogue that retains its historical “6840” code prefix (deliberately preserved to avoid forcing already-registered products through re-registration due to a code change). China’s approach is closer to “look it up in a dictionary” than “find a comparable product.”
- The EU: here’s a point often overlooked — the EU governs “general medical devices” and “in vitro diagnostics” under two entirely separate regulations and classification letter systems. General medical devices fall under the MDR (Medical Device Regulation), classified I/IIa/IIb/III. IVD products fall under the separate IVDR (In Vitro Diagnostic Medical Device Regulation), using a distinct A/B/C/D letter classification, with Class D being the highest risk (e.g., products used for blood screening or detecting high-risk diseases). EU classification is determined by working through a full set of specific rules laid out in MDR Annex VIII / IVDR Annex VIII.
What this means: you can’t assume “this product is Class II in the US, so it’s probably a similar class in China or the EU” — the three systems’ underlying logic differs, and the outcome can be genuinely different. A frequently cited real example: contact lenses are Class III (the highest risk category) in China, but only Class II in the US — the same product, differing by a full risk tier simply because the two regulatory systems weight factors like prolonged eye contact differently, with registration timelines and costs differing by a multiple as a result.
2. A commonly misunderstood point: classification is driven by actual intended use, not the product’s name
China’s drug regulator has cited two examples in its own guidance documents that illustrate this well:
- Glycated hemoglobin elution solution: this product cannot be registered on its own, because it can’t independently accomplish a clinical testing purpose and isn’t a generic sample-processing reagent — it must be registered as part of a complete kit together with the other reagents it’s used with.
- Platelet-rich plasma extraction reagent: despite sounding like an IVD reagent by name, if the extracted plasma is actually used for treatment purposes (cartilage repair, ophthalmology, wound care) rather than diagnostic testing, it doesn’t fall under the definition of an IVD reagent at all and isn’t included in the IVD classification catalogue.
The lesson from both examples: what determines classification is “what this thing is actually used for,” not “what it’s called or what it’s made of.” The same logic applies to software — a diagnostic software tool that only records and organizes data, versus one that actively generates automated diagnostic recommendations, may land in completely different risk classes even with similar underlying algorithms, because the latter has a more direct influence on clinical decision-making.
3. A specific deadline worth knowing right now: January 1, 2027
If you work with Chinese IVD manufacturers or suppliers, this timeline is worth remembering: China published a revised IVD Classification Catalogue in 2024, adjusting the risk class for certain products. For any product whose classification moved from a lower class to a higher class under the new catalogue, the manufacturer must obtain registration meeting the new, higher-class requirements before January 1, 2027 — after which the product cannot legally be manufactured, imported, or sold.
What this means for you: if a Chinese IVD supplier you rely on has a product that was reclassified to a higher risk tier in this catalogue update, and they haven’t completed registration under the new requirements, your supply chain could be disrupted starting in 2027. Worth proactively confirming with your supplier: did your product’s classification change under the 2024 catalogue update? If so, where does registration currently stand?
4. China’s classification isn’t static — a new dynamic adjustment mechanism launched in 2026
On June 1, 2026, the NMPA released two new documents (a “Classification Adjustment Announcement” and “Working Procedure for Dynamic Adjustment of the Medical Device Classification Directory”), establishing a more systematic mechanism for adjusting classifications going forward — covering not just a product’s management class (I/II/III), but potentially even whether it counts as a medical device at all, subject to new evidence and applications. This means even a classification you’ve verified as correct today isn’t guaranteed to stay that way — building a habit of periodically re-checking a supplier’s product classification status matters more than a one-time verification.
The bottom line
Classification of IVDs and medical devices in the US, China, and EU differs not just in risk thresholds, but in the underlying methodology itself — FDA compares against similar products, China looks it up in a catalogue, and the EU works through a rule set. The same product can land in genuinely different classes across the three (contact lenses being the clearest example). What determines classification is actual intended use, not the product’s name or composition. If you work with Chinese IVD suppliers, the January 1, 2027 reclassification deadline, and China’s newly established dynamic adjustment mechanism, are both worth proactively verifying now.
Regulatory details reflect FDA classification rules (21 CFR Parts 800-898), China’s NMPA Medical Device and IVD Classification Catalogues (2024 revision), and the EU’s MDR (2017/745) and IVDR (2017/746) as of mid-2026. This article covers regulatory classification frameworks only and contains no clinical or diagnostic guidance. Verify current classification status for any specific product against official FDA, NMPA, and EU sources, or qualified regulatory counsel, before making business decisions. General guidance, not legal or regulatory advice.